The United Bio-Technology (Hengqin) Co., Ltd.

9 clinical trials · Sponsor

Record	Firm	Date
Phase III Trial of UBT251 in Moderate-to-Severe OSA With Obesity: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. (NCT07767942)	The United Bio-Technology (Hengqin) Co., Ltd.	2026-09-18
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1） (NCT07659574)	The United Bio-Technology (Hengqin) Co., Ltd.	2026-08-10
Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) (NCT07653477)	The United Bio-Technology (Hengqin) Co., Ltd.	2026-07-30
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Subcutaneous UBT38006 Injection in Healthy Adult Males (NCT07630233)	The United Bio-Technology (Hengqin) Co., Ltd.	2026-06-19
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) (NCT07145151)	The United Bio-Technology (Hengqin) Co., Ltd.	2025-09-30
UBT251 Injection Phase II Clinical Study (CKD) (NCT07134335)	The United Bio-Technology (Hengqin) Co., Ltd.	2025-09-01
UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study (NCT07163624)	The United Bio-Technology (Hengqin) Co., Ltd.	2025-03-22
UBT251 Injection Phase II Study (Overweight or Obesity) (NCT07177469)	The United Bio-Technology (Hengqin) Co., Ltd.	2025-03-14

Every clearance here is in the API, with alerts when new ones post.